Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Life Sci Alliance
; 5(12)2022 08 12.
Article
in English
| MEDLINE | ID: covidwho-1994892
ABSTRACT
SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Paraproteinemias
/
Monoclonal Gammopathy of Undetermined Significance
/
COVID-19
Type of study:
Observational study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS